Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
The Journal of Rheumatology
|
June 3, 2009
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial
S Aubrey Stoch, Kenneth G Saag, Maria Greenwald, et al.
Applied and Environmental Microbiology
|
December 5, 2006
Characterization of a large, stable, high-copy-number Streptomyces plasmid that requires stability and transfer functions for heterologous polyketide overproduction
Ryan Fong, Jonathan A Vroom, Zhihao Hu, et al.
Arthritis Research & Therapy
|
March 29, 2020
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
Mark C Genovese, Juan Sanchez-Burson, MyungShin Oh, et al.
Arthritis and Rheumatism
|
March 29, 2002
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
Stanley Cohen, Eric Hurd, John Cush, et al.
The Journal of Rheumatology
|
April 1, 2005
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
Philip J Mease, Ellen M Ginzler, Oscar S Gluck, et al.
British Journal of Clinical Pharmacology
|
February 25, 2016
A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
Stanley Cohen, Paul Emery, Maria Greenwald, et al.
Arthritis and Rheumatism
|
July 13, 2002
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
Larry W Moreland, Rieke Alten, Filip Van den Bosch, et al.
American Journal of Clinical Dermatology
|
August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Alan Menter, Stanley Cohen, Jonathan Kay, et al.
Seminars in Arthritis and Rheumatism
|
September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population
Alan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
September 18, 2021
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
Kenneth G Saag, Michele T McDermott, Jonathan Adachi, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
The Journal of Rheumatology
|
June 3, 2009
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial
S Aubrey Stoch, Kenneth G Saag, Maria Greenwald, et al.
Applied and Environmental Microbiology
|
December 5, 2006
Characterization of a large, stable, high-copy-number Streptomyces plasmid that requires stability and transfer functions for heterologous polyketide overproduction
Ryan Fong, Jonathan A Vroom, Zhihao Hu, et al.
Arthritis Research & Therapy
|
March 29, 2020
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
Mark C Genovese, Juan Sanchez-Burson, MyungShin Oh, et al.
Arthritis and Rheumatism
|
March 29, 2002
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
Stanley Cohen, Eric Hurd, John Cush, et al.
The Journal of Rheumatology
|
April 1, 2005
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
Philip J Mease, Ellen M Ginzler, Oscar S Gluck, et al.
British Journal of Clinical Pharmacology
|
February 25, 2016
A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
Stanley Cohen, Paul Emery, Maria Greenwald, et al.
Arthritis and Rheumatism
|
July 13, 2002
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
Larry W Moreland, Rieke Alten, Filip Van den Bosch, et al.
American Journal of Clinical Dermatology
|
August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Alan Menter, Stanley Cohen, Jonathan Kay, et al.
Seminars in Arthritis and Rheumatism
|
September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population
Alan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
September 18, 2021
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
Kenneth G Saag, Michele T McDermott, Jonathan Adachi, et al.
Page
of 12